News • Cardiac ablation techniques compared

Atrial fibrillation: Study makes economic case for pulsed field ablation

A new multi-country European study demonstrates that pulsed field ablation (PFA) using the Farapulse system delivers measurable economic and operational benefits compared with cryoablation and radiofrequency (RF) ablation for the treatment of paroxysmal atrial fibrillation.

Product photo of a blue and white pulsed field ablation system against a clean white background

The analysis, published in the Journal of Medical Economics, includes data from 270 procedures performed across three European centres in Prague, Modena and Valencia, representing the first multi-country economic evaluation of PFA in Europe.

Key findings:

PFA showed cost savings of 10% compared with cryoablation and 22% compared with RF ablation, mainly driven by shorter procedure duration.
Cost per responder was €2,406 for PFA, compared with €2,873 for cryo (+19%) and €3,436 for RF (+43%).
Consistent and predictable procedure duration improves lab efficiency and capacity planning.

These findings highlight how innovation in ablation technology can support more predictable and sustainable healthcare delivery – particularly as health systems across Europe seek to optimise resources and reduce patient waiting lists.

Source: Boston Scientific

06.02.2026

News • Implant longevity

Smart feature management to extend pacemaker battery life

Pacemakers have a range of different functions, not all of which are needed for every patient – switching off unnecessary features could help extend the battery life of the devices by several years.

News • Flying lifesavers

Sending defibrillator drones to respond to cardiac arrests

A new study demonstrates drones can deliver life-saving AEDs in just minutes from an emergency call – potentially doubling survival rates in out-of-hospital cardiac arrests.

News • Study on vascular access options

Intraosseous or intravenous: which way to administer medication during cardiac arrest?

Research shows a one-third chance of restoring blood circulation during cardiac arrest, regardless of whether the medication is administered into the bloodstream or bone marrow.